S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
Log in
NASDAQ:ALXN

Alexion Pharmaceuticals Stock Forecast, Price & News

$150.10
+1.64 (+1.10 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$148.18
Now: $150.10
$150.56
50-Day Range
$148.19
MA: $155.58
$161.75
52-Week Range
$72.67
Now: $150.10
$162.60
Volume3.06 million shs
Average Volume2.87 million shs
Market Capitalization$33.00 billion
P/E Ratio35.07
Dividend YieldN/A
Beta1.33
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Alexion Pharmaceuticals logo

Headlines

AstraZeneca Sees Profit Accelerating After Turnaround Effort
February 11, 2021 |  finance.yahoo.com
ALXN March 26th Options Begin Trading
February 5, 2021 |  nasdaq.com
Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates
February 4, 2021 |  finance.yahoo.com
Alexion Reports Fourth Quarter and Full Year 2020 Results
February 4, 2021 |  finance.yahoo.com
Is Alexion Pharmaceuticals a Smart Buy for 2021?
January 27, 2021 |  stocknews.com
J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat
January 26, 2021 |  finance.yahoo.com
ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?
January 26, 2021 |  finance.yahoo.com
ALXN March 5th Options Begin Trading
January 21, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ALXN
CUSIP01535110
Phone475-230-2596
Employees3,082
Year Founded1992

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.99 billion
Cash Flow$11.21 per share
Book Value$50.91 per share

Profitability

Net Income$2.40 billion

Miscellaneous

Market Cap$33.00 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

109th out of 1,969 stocks

Pharmaceutical Preparations Industry

43rd out of 771 stocks

Analyst Opinion: 2.2Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$150.10
+1.64 (+1.10 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALXN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions

Is Alexion Pharmaceuticals a buy right now?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 16 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Alexion Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares.
View analyst ratings for Alexion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Alexion Pharmaceuticals?

Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Alexion Pharmaceuticals?

Alexion Pharmaceuticals saw a increase in short interest in February. As of February 12th, there was short interest totaling 7,900,000 shares, an increase of 80.4% from the January 28th total of 4,380,000 shares. Based on an average daily volume of 2,930,000 shares, the short-interest ratio is currently 2.7 days. Approximately 3.6% of the shares of the company are sold short.
View Alexion Pharmaceuticals' Short Interest
.

When is Alexion Pharmaceuticals' next earnings date?

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Alexion Pharmaceuticals
.

How were Alexion Pharmaceuticals' earnings last quarter?

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) issued its quarterly earnings results on Wednesday, February, 3rd. The biopharmaceutical company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.56 by $0.40. The biopharmaceutical company earned $1.59 billion during the quarter, compared to the consensus estimate of $1.51 billion. Alexion Pharmaceuticals had a trailing twelve-month return on equity of 23.16% and a net margin of 16.32%. The business's quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the firm posted $2.71 EPS.
View Alexion Pharmaceuticals' earnings history
.

How has Alexion Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ALXN shares have increased by 79.2% and is now trading at $150.10.
View which stocks have been most impacted by COVID-19
.

What guidance has Alexion Pharmaceuticals issued on next quarter's earnings?

Alexion Pharmaceuticals issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.95 billion, compared to the consensus revenue estimate of $5.99 billion.

What price target have analysts set for ALXN?

24 analysts have issued 12 month price objectives for Alexion Pharmaceuticals' shares. Their forecasts range from $73.00 to $196.00. On average, they expect Alexion Pharmaceuticals' share price to reach $155.00 in the next year. This suggests a possible upside of 3.3% from the stock's current price.
View analysts' price targets for Alexion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alexion Pharmaceuticals' key executives?

Alexion Pharmaceuticals' management team includes the following people:
  • Dr. Ludwig N. Hantson, CEO & Director (Age 58, Pay $3.7M) (LinkedIn Profile)
  • Dr. Aradhana Sarin M.D., Exec. VP & CFO (Age 46, Pay $1.5M) (LinkedIn Profile)
  • Mr. Brian M. Goff, Exec. VP and Chief Commercial & Global Operations Officer (Age 52, Pay $1.68M) (LinkedIn Profile)
  • Dr. John J. Orloff, Exec. VP and Head of R&D (Age 64, Pay $1.76M) (LinkedIn Profile)
  • Mr. Daniel A. Bazarko CPA, Chief Accounting Officer & Sr. VP
  • Mr. Christopher J. Stevo CFA, Head of Investor Relations
  • Ms. Indrani M. Lall Franchini, Exec. VP & Chief Compliance Officer (Age 49) (LinkedIn Profile)
  • Ms. Ellen V. Chiniara J.D., Esq., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 62) (LinkedIn Profile)
  • Megan Goulart, Sr. Director of Corp. Communications
  • Becky Lillie, Interim Chief Human Experience Officer

What is Ludwig Hantson's approval rating as Alexion Pharmaceuticals' CEO?

43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees.

Who are some of Alexion Pharmaceuticals' key competitors?

What other stocks do shareholders of Alexion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V).

What is Alexion Pharmaceuticals' stock symbol?

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Who are Alexion Pharmaceuticals' major shareholders?

Alexion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.30%), FMR LLC (2.87%), Clearbridge Investments LLC (2.68%), Renaissance Technologies LLC (1.88%), Norges Bank (1.44%) and The Manufacturers Life Insurance Company (1.28%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini and Tanisha Carino.
View institutional ownership trends for Alexion Pharmaceuticals
.

Which institutional investors are selling Alexion Pharmaceuticals stock?

ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, AJO LP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, and Clearbridge Investments LLC. Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino.
View insider buying and selling activity for Alexion Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Alexion Pharmaceuticals stock?

ALXN stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Magnetar Financial LLC, Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Westchester Capital Management LLC, Alpine Associates Management Inc., Carlson Capital L P, and Water Island Capital LLC.
View insider buying and selling activity for Alexion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alexion Pharmaceuticals?

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alexion Pharmaceuticals' stock price today?

One share of ALXN stock can currently be purchased for approximately $150.10.

How much money does Alexion Pharmaceuticals make?

Alexion Pharmaceuticals has a market capitalization of $33.00 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis.

How many employees does Alexion Pharmaceuticals have?

Alexion Pharmaceuticals employs 3,082 workers across the globe.

When was Alexion Pharmaceuticals founded?

Alexion Pharmaceuticals was founded in 1992.

What is Alexion Pharmaceuticals' official website?

The official website for Alexion Pharmaceuticals is www.alexion.com.

Where are Alexion Pharmaceuticals' headquarters?

Alexion Pharmaceuticals is headquartered at 121 SEAPORT BOULEVARD, BOSTON MA, 02210.

How can I contact Alexion Pharmaceuticals?

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]


This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.